Current and historical daily PE Ratio for Revelation Biosciences Inc (
) from 2022 to May 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Revelation Biosciences stock (FRA:56U0) PE ratio as of May 29 2024 is 0.
More Details
Revelation Biosciences Inc (FRA:56U0) PE Ratio (TTM) Chart
Revelation Biosciences Inc (FRA:56U0) PE Ratio (TTM) Historical Data
View and export this data going back to 2022. Start your Free Trial
Total 394
- 1
- 2
- 3
- 4
- 5
| Revelation Biosciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-29 | At Loss | 2024-03-21 | 1.1 |
| 2024-05-22 | At Loss | 2024-03-20 | 1.1 |
| 2024-05-21 | At Loss | 2024-03-19 | 1.1 |
| 2024-05-20 | At Loss | 2024-03-18 | 1.1 |
| 2024-05-17 | At Loss | 2024-03-15 | 1.1 |
| 2024-05-16 | At Loss | 2024-03-14 | 1.1 |
| 2024-05-15 | At Loss | 2024-03-13 | 1.1 |
| 2024-05-14 | At Loss | 2024-03-12 | 1.1 |
| 2024-05-13 | At Loss | 2024-03-11 | 1.1 |
| 2024-05-10 | At Loss | 2024-03-08 | 1.1 |
| 2024-05-09 | At Loss | 2024-03-07 | 1.1 |
| 2024-05-08 | At Loss | 2024-03-06 | 1.1 |
| 2024-05-07 | At Loss | 2024-03-05 | 1.1 |
| 2024-05-06 | At Loss | 2024-03-04 | 1.1 |
| 2024-05-03 | At Loss | 2024-03-01 | 1.1 |
| 2024-05-02 | At Loss | 2024-02-29 | 1.1 |
| 2024-05-01 | At Loss | 2024-02-28 | 1.1 |
| 2024-04-30 | At Loss | 2024-02-27 | 1.1 |
| 2024-04-29 | At Loss | 2024-02-26 | 1.1 |
| 2024-04-26 | At Loss | 2024-02-23 | 1.1 |
| 2024-04-25 | At Loss | 2024-02-22 | 1.1 |
| 2024-04-24 | At Loss | 2024-02-21 | 1.1 |
| 2024-04-23 | At Loss | 2024-02-20 | 1.1 |
| 2024-04-22 | At Loss | 2024-02-19 | 1.1 |
| 2024-04-19 | At Loss | 2024-02-16 | 1.1 |
| 2024-04-18 | At Loss | 2024-02-15 | 1.1 |
| 2024-04-17 | At Loss | 2024-02-14 | 1.1 |
| 2024-04-16 | At Loss | 2024-02-13 | 1.1 |
| 2024-04-15 | At Loss | 2024-02-12 | 1.1 |
| 2024-04-12 | At Loss | 2024-02-09 | 1.1 |
| 2024-04-11 | At Loss | 2024-02-08 | 1.1 |
| 2024-04-10 | At Loss | 2024-02-07 | 1.1 |
| 2024-04-09 | At Loss | 2024-02-06 | 1.1 |
| 2024-04-08 | At Loss | 2024-02-05 | 1.1 |
| 2024-04-05 | At Loss | 2024-02-02 | 1.1 |
| 2024-04-04 | At Loss | 2024-02-01 | 1.1 |
| 2024-04-03 | At Loss | 2024-01-31 | 1.1 |
| 2024-04-02 | At Loss | 2024-01-30 | 1.1 |
| 2024-04-01 | At Loss | 2024-01-29 | 1.1 |
| 2024-03-29 | At Loss | 2024-01-26 | 1.1 |
| 2024-03-28 | At Loss | 2024-01-25 | 1.1 |
| 2024-03-27 | 1.1 | 2024-01-24 | 1.1 |
| 2024-03-26 | 1.1 | 2024-01-23 | 1.3 |
| 2024-03-25 | 1.1 | 2024-01-22 | 1.3 |
| 2024-03-22 | 1.1 | 2024-01-19 | 1.4 |
Revelation Biosciences Inc (FRA:56U0) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Revelation Biosciences Inc
NAICS : 541715
SIC : 2834
ISIN : US76135L5075
Share Class Description:
FRA:56U0: Ordinary SharesDescription
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers